Why US Pharma Can't Compete with India's Generics I ft. Dr. Marschall Runge I Ep50

About

Why do US pharma companies struggle in India's generic drug market, and what does the future hold for US-India collaboration?

Dr. Marschall Runge, Former CEO of the University of Michigan Medical School and former Board of Directors at Eli Lilly, breaks down the competitive dynamics between US innovation-driven pharma and India's generic drug dominance.

In this conversation, we discuss:

Why US companies can't compete on generics (and shouldn't try)
India's untapped opportunity in biosimilars
The Mark Cuban Cost Plus Drugs model
US-India pharma partnerships: realistic or wishful thinking?
How AI will transform healthcare delivery
Why obesity is the #1 health problem to solve
The problem with Pharmacy Benefit Managers (PBMs)
Healthcare as business vs. common good

Dr. Runge's take: "India has excelled at high-quality drugs at low cost. US companies focused on patent drugs with higher margins. But I see tremendous opportunity for collaboration, especially in biosimilars.

ABOUT DR. MARSCHALL RUNGE:

Dr. Runge is Former CEO of the University of Michigan Medical School and a distinguished physician. He previously served on the Independent Directors at Eli Lilly and is a leading advocate for integrating advanced technology into healthcare systems.

His expertise spans academic medicine, pharmaceutical innovation, and healthcare policy.

CONNECT WITH DR. RUNGE:

LinkedIn: / marschallsrunge

LISTEN ON PODCAST:

Apple Podcasts: https://podcasts.apple.com/us/podcast...

Spotify: https://open.spotify.com/show/4EDgDoe...

Website: https://gameofpharma.com/

GAME OF PHARMA NEWSLETTER:

Weekly pharma insights delivered to your inbox

Subscribe: https://game-of-pharma.beehiiv.com

CONNECT WITH HOST - LOKESH SHARMA

LinkedIn: / lokesh-sharma-7250a71a9